Biotechnology Startup Funding 2025-2026

What are all the funding deals in the biotechnology market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play biotechnology companies between July 2025 and June 2026. We count as pure-play biotechnology companies those applying modern biological science and engineering to improve medical or life-science outcomes.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, and the main investors when specified in the dataset. For a wider view of how biotechnology fits inside the broader life-science opportunity, we cover it in our Biotechnology market report.

How active has fundraising been in the biotechnology market?

As of June 2026, fundraising in the biotechnology market has been highly active across the 12 months studied. Companies raised 128 disclosed equity rounds and $16.976B combined, which works out to 10.7 deals per month.

The deal count shows a broad financing market, not a handful of isolated announcements. The dataset includes 125 unique companies, so nearly every round represents a distinct company rather than repeated refinancing.

Dollar flow is large but uneven. Monthly capital averaged $1.415B, while the monthly median was $1.226B, which means the market maintained billion-dollar funding months even outside the biggest spike.

May 2026 is the clearest example of distortion. Only 4 deals were announced that month, but they raised $2.355B because Isomorphic Labs alone raised $2.1B.

If you want a broader view of where this activity points next, see our biotechnology market report.

How concentrated has fundraising been in the biotechnology market?

As of June 2026, fundraising in the biotechnology market is concentrated, but not dominated by a single company. Over the 12 months studied, the largest deal accounts for 12.37% of capital, the top 3 reach 18.47%, and the top 10 reach 31.18%.

This is a meaningful power-law pattern, but it is not extreme by frontier-market standards. Even after the top 10 deals, almost 69% of disclosed capital remains distributed across the rest of the dataset.

The bigger concentration signal appears by category. Therapeutics Discovery Platforms capture $13.168B, or 77.57% of all disclosed capital, which makes the biotechnology market heavily centered on therapeutic pipelines and discovery engines.

Geography adds another layer of concentration. North America captures 63.45% of disclosed capital and 67.19% of disclosed deals, so the funding market is broad by company count but still geographically anchored.

How much of the biotechnology funding signal is driven by outliers?

As of June 2026, the biotechnology funding signal is influenced by outliers, but less dependent on them than the headline numbers suggest. Over the 12 months studied, the top 10 deals account for 31.18% of disclosed capital.

The Isomorphic Labs round is the largest single outlier at $2.1B. It alone represents 12.37% of all disclosed biotechnology funding, so any monthly or average figure should be read with that deal in mind.

At the same time, the biotechnology market has a deep middle. The median round is $100M, and 58 disclosed rounds cleared $100M, which means large financings are not limited to a tiny elite.

The cleanest reading is that biotechnology has both outliers and breadth. Big rounds shape the narrative, but the dataset still shows repeated institutional funding across many companies and stages.

Is the biotechnology market broad with many targets, or narrow with few fundable companies?

As of June 2026, the biotechnology market is broad by company count and deal volume. Over the 12 months studied, 125 unique companies raised 128 disclosed equity rounds.

That near one-to-one ratio matters. It means the dataset is not mainly one group of companies coming back for multiple extensions during the same period.

Category breadth is narrower than company breadth. Therapeutics Discovery Platforms alone account for 95 of 128 deals, while Diagnostic Technology Firms account for only 2 and Bioprocessing Tool Providers have no disclosed deals in the dataset.

So the biotechnology market is broad as a financing universe, but narrow in what investors are funding most aggressively. The center of gravity is still therapeutic discovery, not the full life-science stack.

Is biotechnology mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the biotechnology market is balanced by deal count but late-stage by capital. Over the 12 months studied, early-stage rounds account for 30.02% of capital, while late-stage rounds account for 60.27%.

Series A and Series B dominate the visible market by activity. Series A has 45 deals, Series B has 44, and together they represent almost 70% of the full dataset.

The dollars tilt later because Series B is the largest capital bucket. Series B rounds raised $6.861B, or 40.42% of all disclosed biotechnology capital.

Series A is still substantial, with $4.744B raised and an average round size of $105.4M. That confirms biotechnology company formation remains expensive even before companies reach traditional growth stages.

For more context on stage signals in this market, explore our deeper analysis of biotechnology fundraising.

Which categories attract the most investor attention in biotechnology?

As of June 2026, Therapeutics Discovery Platforms attract the most investor attention in biotechnology. Over the 12 months studied, they captured 95 of 128 deals and $13.168B in disclosed capital.

That category alone represents 74.22% of deal count and 77.57% of capital. In practical terms, most visible biotechnology funding is still a bet on therapeutic pipelines, biologics, ADCs, RNA medicines, and discovery platforms.

Gene Editing Companies rank second with 17 deals and $2.288B raised. The category is much smaller than therapeutics discovery, but its 13.48% capital share shows sustained institutional interest.

Cell Therapy Developers are visible but smaller, with 10 deals and $834M. Synthetic Biology Platforms raise fewer rounds, but their $141.8M average deal size is the highest category average in the dataset.

Which categories attract disproportionately large checks in the biotechnology market?

As of June 2026, Synthetic Biology Platforms attract disproportionately large checks in the biotechnology market. Over the 12 months studied, they account for only 3.13% of deals but 3.34% of capital, giving the category a 1.07 capital-to-deal ratio.

Therapeutics Discovery Platforms also slightly over-index. They hold 74.22% of deals and 77.57% of capital, which gives them a 1.05 ratio and confirms that the dominant category also receives above-par check sizes.

Gene Editing Companies sit close to parity with a 1.01 ratio. That means their funding share roughly matches their deal share, even though individual rounds such as NewLimit and Kriya are large.

Cell Therapy Developers and Diagnostic Technology Firms under-index on capital. Cell therapy has a 0.63 ratio, while diagnostics has a 0.45 ratio, showing weaker dollar intensity relative to deal count.

Which geographies matter most for fundraising in the biotechnology market?

As of June 2026, North America matters most for biotechnology fundraising. Over the 12 months studied, it captured 86 of 128 deals and $10.772B, equal to 63.45% of disclosed capital.

Europe is the second-largest geography by capital, with $4.100B across 20 deals. Its average deal size is $205M, the highest regional average, because the $2.1B Isomorphic Labs round heavily lifts the total.

Asia-Pacific is more active than Europe by deal count but smaller by dollars. It produced 22 deals and $2.104B, or 12.39% of disclosed capital.

The geography split shows three different roles. North America supplies the main market depth, Europe produces occasional very large platform bets, and Asia-Pacific contributes a steady but smaller funding bench.

We cover these regional patterns in more detail in our market report covering biotechnology geography.

Is biotechnology a market of small experiments or scaled financings?

As of June 2026, biotechnology is a market of scaled financings, not small experiments. Over the 12 months studied, 126 of 128 disclosed rounds were $50M or larger.

The size distribution is striking. There were no disclosed deals below $5M, only 1 deal between $5M and $20M, and only 1 deal between $20M and $50M.

The median round size is $100M, and 58 deals cleared $100M. This means the visible biotechnology market is already dominated by institutional-scale financings.

The average round size is $132.6M, but that number is lifted by outliers. The median is the cleaner reading of what a typical disclosed biotechnology round looks like at this scale.

If you want to stay close to the funding signals behind these financings, read our full market deck on biotechnology.

Who are the investors that appear the most in biotechnology fundraising?

As of June 2026, OrbiMed appears most often in biotechnology fundraising. Over the 12 months studied, OrbiMed appears in 18 disclosed deals, followed by RA Capital Management with 15 and Forbion with 10.

The next tier is also highly active. Qiming Venture Partners appears in 9 deals, while ARCH Venture Partners, Janus Henderson Investors, and SR One each appear in 8.

This repeat-investor pattern is important because biotechnology requires specialized underwriting. Investors are not only financing companies; they are judging biology, clinical risk, modality risk, and regulatory path.

One important caveat is that round announcements rarely disclose each investor’s individual check size. The repeat counts show participation frequency, not the exact capital committed by each investor.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.